Is time to progression in metastatic breast cancer patients treated with epirubicin improved by the addition of either cisplatin or lonidamine : final results of a phase III study with a factorial design?
Neither CDDP nor LND was able to significantly improve the time to progression obtained by EPI. CDDP, however, significantly worsened the drug's tolerability.
These data suggest that reduced mtDNA content may be a possible early marker of dementia, and this finding warrants further study in large, prospective investigations.